{"id":649218,"date":"2023-04-26T18:36:01","date_gmt":"2023-04-26T18:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649218"},"modified":"2023-04-26T18:36:01","modified_gmt":"2023-04-26T18:36:01","slug":"cataplexy-market-cm-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cataplexy-market-cm-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics_649218.html","title":{"rendered":"Cataplexy Market (CM) to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies &#8211; Axome Therapeutics, Suven Therapeutics, Takeda, Avel Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cataplexy Market (CM) to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Axome Therapeutics, Suven Therapeutics, Takeda, Avel Therapeutics \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Cataplexy Market (CM) to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Axome Therapeutics, Suven Therapeutics, Takeda, Avel Therapeutics \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cataplexy Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cataplexy Market Insights, Epidemiology, and Market Forecast-2032<\/a>&#8220;<\/strong> report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Cataplexy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. Subjective descriptions of cataplexy can assist in identifying narcolepsy, as this feature is all but unique to the disorder. Unfortunately, cataplexy is challenging to identify, often going undetected. While 19% of patients diagnosed with narcolepsy also get diagnosed with cataplexy, estimates are that roughly 70% of patients with narcolepsy also have cataplexy.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/7ccf5f44ea2ac3e06b99e80f3d32e9b7.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>The Report Covers the Cataplexy&nbsp; Epidemiology Segmented by &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; treatment cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cataplexy&nbsp; Market Landscape&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Cataplexy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cataplexy market trends by analyzing the impact of current Cataplexy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of the Cataplexy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cataplexy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Cataplexy market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Cataplexy Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Axome Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Suven Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avel Therapeutics&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Therapies Covered in the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SUVN-G3031<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AXS-12 (reboxetine)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">FT218<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TAK-861<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Cataplexy Market&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Cataplexy&nbsp; Market&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; Market Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cataplexy&nbsp; Market Cancer Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about detailed report offerings @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cataplexy&nbsp; Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cataplexy-market-cm-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cataplexy-market-cm-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Cataplexy Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU4 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cataplexy-market-cm-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics_649218.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-649218","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=649218"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649218\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=649218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=649218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=649218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}